Inactive Instrument

Highlights Nymox Pharmaceutical Corporation Nasdaq

Equities

CA67076P1027

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH	23-09-25	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results	23-07-25	CI
Fed Outlook Weighs on Exchange-Traded Funds, Equity Futures Premarket Thursday	23-07-06	MT
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Nymox Pharmaceutical Gets Nasdaq Extension to Comply With Listing Requirements; Shares Rise	23-03-15	MT
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH	22-12-05	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
NYMOX Receives RTF letter from FDA	22-05-23	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Nymox Pharma Seeks FDA Marketing Nod for Fexapotide Triflutate Drug Candidate; Shares Rise	22-03-03	MT
Nymox Pharmaceutical Corporation Announces Submission of New Drug Application to the FDA for Fexapotide Triflutate	22-03-03	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Nymox Pharmaceutical : Expects to Provide Guidance on Fexapotide Regulatory Filing This Quarter; Shares Drop	21-10-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nymox Pharmaceutical Corporation Nasdaq

Equities

CA67076P1027

Highlights

Filters